Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Investigators Finding Fewer Deficiencies For Visual Inspection Programs

Executive Summary

Experts on visual inspection and patient risk attribute a downward trend in inadequate visual inspection plans for particles to a new USP chapter that offers greater clarity on testing conditions. While there is negligible safety risk posed by visible particles, manufacturers should still conduct particle characterization studies. And no, glass particles are not risker than metal or wood particles.

You may also be interested in...



Pfizer Suffered 'Significant Loss Of Control' At McPherson Plant, US FDA Warning Letter Says

Infractions that have delayed Copaxone generic in plant Pfizer acquired when it bought Hospira suggest that pattern of quality issues may be continuing. Warning letter assigns eight tasks related to particulate contamination.

FDA Taking Closer Look at Manufacturers’ Visual Testing Programs While USP Would Set New Limits for Particles

FDA investigators are taking a closer look at parenteral manufacturers’ inspections for visible particles while a proposed USP standard would give more guidance – and much needed clarity – on establishing acceptable quality limits for particles and setting up visual inspection programs.

Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others

Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”

Topics

UsernamePublicRestriction

Register

PS119213

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel